Print E-mail
Volume 41, Number 4, August 2008

In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae


Yee-Huang Ku, Yin-Ching Chuang, Wen-Liang Yu
Division of Infectious Disease, Department of Internal Medicine, Chi Mei Medical Center, Liouying; Departments of Medical Research and Intensive Care Medicine, Chi-Mei Medical Center, Tainan; and Department of Medicine, Taipei Medical University, Taipei, Taiwan

Received: April 5, 2007    Revised: May 15, 2007    Accepted: June 25, 2007   

 

Corresponding author:

Dr. Wen-Liang Yu, Department of Intensive Care Medicine, Chi-Mei Medical Center, Tainan, Taiwan. E-mail: Dr. Wen-Liang Yu This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
 



 

Background and purpose: 

Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.

 



 

Methods:

104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips.

 



 

Results:

The minimal tigecycline concentration at which 50% of isolates were inhibited and minimal concentration at which 90% of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 μg/mL and 0.5 to 1.5 μg/mL, respectively.

 



 

Conclusion:

Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.

 



 

Key words:

beta-Lactamase resistance; beta-Lactamases; Enterobacteriaceae; Microbial sensitivity tests; Minocycline

 



 

J Microbiol Immunol Infect. 2008;41:332-336.